Structural modifications of bryostatin 2

G. R. Pettit, D. Sengupta, P. M. Blumberg, N. E. Lewin, J. M. Schmidt, A. S. Kraft

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Continuation of a structure/activity relationship study of the bryostatins was focused on bryostatin 2. Stepwise catalytic hydrogenation of bryostatin 2 gave the following results. Reduction of the side-chain diene system to saturated ester 2a (P388 cell line ED50 8.5 x 10-3 μg/ml) did not significantly affect thc murine P388 cell line inhibition by bryostatin 2. Further hydrogenation to hexahydro derivative 2b gave a reduced P388 ED50 of 5.1 x 10-2 μg/ml. Conversion to the octahydrobryostatin 2c caused a further reduction of P388 cell line activity to ED50 2.9 x 10-1 μg/ml. Other structural modifications of bryostatin 2 in respect to esterification at the C-7 position significantly affected the P388 lymphocytic leukemia cell line response. Each of the bryostatin 2 derivatives was also evaluated with respect to protein kinase C binding.

Original languageEnglish (US)
Pages (from-to)101-114
Number of pages14
JournalAnti-Cancer Drug Design
Volume7
Issue number2
StatePublished - 1992

Fingerprint

Cells
Cell Line
Hydrogenation
Bryostatins
Derivatives
Lymphoid Leukemia
Esterification
Structure-Activity Relationship
Protein Kinase C
Esters
bryostatin 2

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Organic Chemistry
  • Oncology
  • Drug Discovery
  • Pharmacology

Cite this

Pettit, G. R., Sengupta, D., Blumberg, P. M., Lewin, N. E., Schmidt, J. M., & Kraft, A. S. (1992). Structural modifications of bryostatin 2. Anti-Cancer Drug Design, 7(2), 101-114.

Structural modifications of bryostatin 2. / Pettit, G. R.; Sengupta, D.; Blumberg, P. M.; Lewin, N. E.; Schmidt, J. M.; Kraft, A. S.

In: Anti-Cancer Drug Design, Vol. 7, No. 2, 1992, p. 101-114.

Research output: Contribution to journalArticle

Pettit, GR, Sengupta, D, Blumberg, PM, Lewin, NE, Schmidt, JM & Kraft, AS 1992, 'Structural modifications of bryostatin 2', Anti-Cancer Drug Design, vol. 7, no. 2, pp. 101-114.
Pettit GR, Sengupta D, Blumberg PM, Lewin NE, Schmidt JM, Kraft AS. Structural modifications of bryostatin 2. Anti-Cancer Drug Design. 1992;7(2):101-114.
Pettit, G. R. ; Sengupta, D. ; Blumberg, P. M. ; Lewin, N. E. ; Schmidt, J. M. ; Kraft, A. S. / Structural modifications of bryostatin 2. In: Anti-Cancer Drug Design. 1992 ; Vol. 7, No. 2. pp. 101-114.
@article{cfeacdadfabf499cbe51392fd5f0f63f,
title = "Structural modifications of bryostatin 2",
abstract = "Continuation of a structure/activity relationship study of the bryostatins was focused on bryostatin 2. Stepwise catalytic hydrogenation of bryostatin 2 gave the following results. Reduction of the side-chain diene system to saturated ester 2a (P388 cell line ED50 8.5 x 10-3 μg/ml) did not significantly affect thc murine P388 cell line inhibition by bryostatin 2. Further hydrogenation to hexahydro derivative 2b gave a reduced P388 ED50 of 5.1 x 10-2 μg/ml. Conversion to the octahydrobryostatin 2c caused a further reduction of P388 cell line activity to ED50 2.9 x 10-1 μg/ml. Other structural modifications of bryostatin 2 in respect to esterification at the C-7 position significantly affected the P388 lymphocytic leukemia cell line response. Each of the bryostatin 2 derivatives was also evaluated with respect to protein kinase C binding.",
author = "Pettit, {G. R.} and D. Sengupta and Blumberg, {P. M.} and Lewin, {N. E.} and Schmidt, {J. M.} and Kraft, {A. S.}",
year = "1992",
language = "English (US)",
volume = "7",
pages = "101--114",
journal = "Anti-Cancer Drug Design",
issn = "0266-9536",
publisher = "Cognizant Communication Corporation",
number = "2",

}

TY - JOUR

T1 - Structural modifications of bryostatin 2

AU - Pettit, G. R.

AU - Sengupta, D.

AU - Blumberg, P. M.

AU - Lewin, N. E.

AU - Schmidt, J. M.

AU - Kraft, A. S.

PY - 1992

Y1 - 1992

N2 - Continuation of a structure/activity relationship study of the bryostatins was focused on bryostatin 2. Stepwise catalytic hydrogenation of bryostatin 2 gave the following results. Reduction of the side-chain diene system to saturated ester 2a (P388 cell line ED50 8.5 x 10-3 μg/ml) did not significantly affect thc murine P388 cell line inhibition by bryostatin 2. Further hydrogenation to hexahydro derivative 2b gave a reduced P388 ED50 of 5.1 x 10-2 μg/ml. Conversion to the octahydrobryostatin 2c caused a further reduction of P388 cell line activity to ED50 2.9 x 10-1 μg/ml. Other structural modifications of bryostatin 2 in respect to esterification at the C-7 position significantly affected the P388 lymphocytic leukemia cell line response. Each of the bryostatin 2 derivatives was also evaluated with respect to protein kinase C binding.

AB - Continuation of a structure/activity relationship study of the bryostatins was focused on bryostatin 2. Stepwise catalytic hydrogenation of bryostatin 2 gave the following results. Reduction of the side-chain diene system to saturated ester 2a (P388 cell line ED50 8.5 x 10-3 μg/ml) did not significantly affect thc murine P388 cell line inhibition by bryostatin 2. Further hydrogenation to hexahydro derivative 2b gave a reduced P388 ED50 of 5.1 x 10-2 μg/ml. Conversion to the octahydrobryostatin 2c caused a further reduction of P388 cell line activity to ED50 2.9 x 10-1 μg/ml. Other structural modifications of bryostatin 2 in respect to esterification at the C-7 position significantly affected the P388 lymphocytic leukemia cell line response. Each of the bryostatin 2 derivatives was also evaluated with respect to protein kinase C binding.

UR - http://www.scopus.com/inward/record.url?scp=0026579522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026579522&partnerID=8YFLogxK

M3 - Article

C2 - 1575884

AN - SCOPUS:0026579522

VL - 7

SP - 101

EP - 114

JO - Anti-Cancer Drug Design

JF - Anti-Cancer Drug Design

SN - 0266-9536

IS - 2

ER -